29 min listen
Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition
Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition
ratings:
Length:
67 minutes
Released:
May 6, 2024
Format:
Podcast episode
Description
Dr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field, moderated by Dr Neil Love. Produced by Research To Practice.
CME information and select publications here (https://www.researchtopractice.com/OncologyTodayHER2PanTumor23/3GU).
CME information and select publications here (https://www.researchtopractice.com/OncologyTodayHER2PanTumor23/3GU).
Released:
May 6, 2024
Format:
Podcast episode
Titles in the series (100)
Dr Harold Burstein on Breast Cancer Treatment and COVID-19 at Dana-Farber: Dr Harold Burstein discusses how breast cancer is currently being managed at the Dana-Farber Cancer Institute with the constraints of social distancing and other COVID-19 considerations. by Oncology Today with Dr Neil Love